Table 2.
Percentage (and total spending) of total variable cost spent on different categories (Patients with CD4+ count ≥ 50 cells/mm3)
| Arm-1 N = 177 |
Arm-2 N = 180 |
Arm-3 N = 172 |
Total N = 529 |
|
|---|---|---|---|---|
| Antiretroviral therapy | 32.4% ($109,224) | 28.7%($80,452) | 17.6%($48,423) | 26.7%($238,098) |
| Other medication | 0.4%($1,351) | 0.6%($1,544) | 0.6%($1,739) | 0.5%($4,634) |
| All investigations | 35.5%($119,456) | 43.0%($120,577) | 40.7%($111,808) | 39.4%($351,837) |
| CD4+ count and viral load | 10.6%($35,731) | 12.2%($34,115) | 11.4%($31,207) | 11.3%($101,054) |
| Safety laboratory tests | 22.7%($76,433) | 28.3%($79,558) | 26.9%($73,953) | 25.8%($229,945) |
| X-rays | 2.2%($7,292) | 2.5%($6,898) | 2.4%($6,648) | 2.3%($20,838) |
| Outpatient consultations | 18.6%($62,527) | 19.7%($55,374) | 18.3%($50,418) | 18.9%($168,319) |
| Hospitalization cost | 12.9%($43,291) | 7.7%($21,710) | 22.4%($61,453) | 14.2%($126,454) |